China gene-editing clinical trial fatalities

Two separate pediatric deaths in Shanghai have been linked to experimental gene-editing clinical trials, raising significant concerns regarding biomedical ethics and regulatory oversight in China.

In one instance, a male patient participating in a HuidaGene Therapeutics trial for Duchenne muscular dystrophy died after developing a severe cytokine storm and acute respiratory distress syndrome following a high dosage of CRISPR/Cas12 therapy. Reports indicate the company may have failed to report the incident promptly.

In a second incident, a six-year-old girl died following treatment for Snijders Blok-Campeau syndrome at Xinhua Hospital. The fatality was reportedly caused by a severe immune reaction and microangiopathy after the administration of an adenine base editor. Allegations have surfaced that the research team omitted details of this death from academic publications to maintain a false impression of the therapy’s safety.

These fatalities have drawn international attention to the risks associated with investigator-initiated trials (IITs), which operate with less direct supervision from drug regulators. Experts suggest these events could damage the credibility of Chinese scientific institutions and prompt stricter government regulations for fast-track clinical trial processes.